| Code | CSB-RA613506MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BI-764524, targeting Semaphorin 3A (SEMA3A), a secreted glycoprotein that plays critical roles in axonal guidance, neural development, and vascular patterning. SEMA3A functions as a chemorepellent by binding to neuropilin-1 (NRP1) and plexin co-receptors, triggering growth cone collapse and regulating cell migration. Beyond its neurobiological functions, SEMA3A is implicated in various pathological conditions including cancer, where it can exert context-dependent effects on tumor progression, angiogenesis, and metastasis. Dysregulated SEMA3A expression has been associated with pain disorders, cardiovascular diseases, and immune dysfunction.
BI-764524 is a clinical-stage therapeutic antibody designed to neutralize SEMA3A activity, initially investigated for its potential in treating cancer and pain-related conditions. This biosimilar provides researchers with a valuable tool for investigating SEMA3A-mediated signaling pathways, exploring its role in disease pathogenesis, and evaluating therapeutic strategies targeting the semaphorin-neuropilin axis. The antibody supports studies in oncology, neuroscience, and vascular biology research.
There are currently no reviews for this product.